Intech Biopharm (Taiwan) Performance
| 6461 Stock | TWD 23.90 0.05 0.21% |
The company retains a Market Volatility (i.e., Beta) of -0.23, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Intech Biopharm are expected to decrease at a much lower rate. During the bear market, Intech Biopharm is likely to outperform the market. At this point, Intech Biopharm has a negative expected return of -0.16%. Please make sure to check out Intech Biopharm's maximum drawdown, potential upside, and the relationship between the treynor ratio and value at risk , to decide if Intech Biopharm performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Intech Biopharm has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors. ...more
| Begin Period Cash Flow | 204.7 M | |
| Total Cashflows From Investing Activities | -35.5 M |
Intech |
Intech Biopharm Relative Risk vs. Return Landscape
If you would invest 2,635 in Intech Biopharm on December 23, 2024 and sell it today you would lose (245.00) from holding Intech Biopharm or give up 9.3% of portfolio value over 90 days. Intech Biopharm is generating negative expected returns and assumes 1.5222% volatility on return distribution over the 90 days horizon. Simply put, 13% of stocks are less volatile than Intech, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Intech Biopharm Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Intech Biopharm's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Intech Biopharm, and traders can use it to determine the average amount a Intech Biopharm's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.105
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 6461 |
Estimated Market Risk
| 1.52 actual daily | 13 87% of assets are more volatile |
Expected Return
| -0.16 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Intech Biopharm is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Intech Biopharm by adding Intech Biopharm to a well-diversified portfolio.
Intech Biopharm Fundamentals Growth
Intech Stock prices reflect investors' perceptions of the future prospects and financial health of Intech Biopharm, and Intech Biopharm fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Intech Stock performance.
| Return On Equity | -0.28 | |||
| Return On Asset | -0.0739 | |||
| Operating Margin | (9.09) % | |||
| Current Valuation | 5.09 B | |||
| Shares Outstanding | 116.96 M | |||
| Price To Book | 3.67 X | |||
| Price To Sales | 128.48 X | |||
| Revenue | 38.9 M | |||
| EBITDA | (196.92 M) | |||
| Total Debt | 940.77 M | |||
| Book Value Per Share | 9.61 X | |||
| Cash Flow From Operations | (200.61 M) | |||
| Earnings Per Share | (2.87) X | |||
| Total Asset | 2.6 B | |||
About Intech Biopharm Performance
Evaluating Intech Biopharm's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Intech Biopharm has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Intech Biopharm has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about Intech Biopharm performance evaluation
Checking the ongoing alerts about Intech Biopharm for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Intech Biopharm help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Intech Biopharm generated a negative expected return over the last 90 days | |
| Intech Biopharm has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 38.9 M. Net Loss for the year was (301.76 M) with loss before overhead, payroll, taxes, and interest of (119.37 M). | |
| Intech Biopharm generates negative cash flow from operations | |
| About 47.0% of the company shares are owned by insiders or employees |
- Analyzing Intech Biopharm's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Intech Biopharm's stock is overvalued or undervalued compared to its peers.
- Examining Intech Biopharm's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Intech Biopharm's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Intech Biopharm's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Intech Biopharm's stock. These opinions can provide insight into Intech Biopharm's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Intech Stock Analysis
When running Intech Biopharm's price analysis, check to measure Intech Biopharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intech Biopharm is operating at the current time. Most of Intech Biopharm's value examination focuses on studying past and present price action to predict the probability of Intech Biopharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intech Biopharm's price. Additionally, you may evaluate how the addition of Intech Biopharm to your portfolios can decrease your overall portfolio volatility.